To ascertain the prognostic relevance of YARS1, we analysed the TCGA‐BLCA data set and discovered that patients with high expression of YARS1 exhibited poorer overall and disease‐specific survival rates (Figure 1E, F). Here, YARS1 is linked to bladder transitional cell carcinoma.